A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors

Colorectal cancer spheroid biobanks: multi-level approaches to drug sensitivity studies

(2018) Maria Laura De Angelis et al.   CELL BIOLOGY AND TOXICOLOGY

Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines

(2018) Waliul Islam et al.   MOLECULAR CANCER THERAPEUTICS

Therapy-induced enrichment of cancer stem-like cells in solid human tumors: Where do we stand?

(2018) Sara R. Martins-Neves et al.   PHARMACOLOGICAL RESEARCH

Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives

(2017) Jason P Cooper et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance

(2016) Maria Laura De Angelis et al.   Stem Cells Translational Medicine

Dynamic regulation of the cancer stem cell compartment by Cripto-1 in colorectal cancer

(2015) F Francescangeli et al.   CELL DEATH AND DIFFERENTIATION

Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer

(2015) G Sette et al.   Cell Death & Disease

Evolution of the Cancer Stem Cell Model

(2014) Antonija Kreso et al.   Cell Stem Cell

A novel cell-cycle-indicator, mVenus-p27K−, identifies quiescent cells and visualizes G0–G1 transition

(2014) Toshihiko Oki et al.   Scientific Reports

Correlation between octanol/water and liposome/water distribution coefficients and drug absorption of a set of pharmacologically active compounds

(2013) Freddy Esteves et al.   JOURNAL OF LIPOSOME RESEARCH

Ablation of Dihydroceramide Desaturase 1, a Therapeutic Target for the Treatment of Metabolic Diseases, Simultaneously Stimulates Anabolic and Catabolic Signaling

(2013) M. M. Siddique et al.   MOLECULAR AND CELLULAR BIOLOGY

TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling

(2013) Paloma Bragado et al.   NATURE CELL BIOLOGY

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium

(2013) Barry J. Maurer et al.   PEDIATRIC BLOOD & CANCER

Preferential eradication of acute myelogenous leukemia stem cells by fenretinide

(2013) H. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Myriocin, a serine palmitoyltransferase inhibitor, suppresses tumor growth in a murine melanoma model by inhibiting de novo sphingolipid synthesis

(2012) Youn-Sun Lee et al.   CANCER BIOLOGY & THERAPY

Dihydroceramide delays cell cycle G1/S transition via activation of ER stress and induction of autophagy

(2012) Vincenzo Gagliostro et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Dormancy Signatures and Metastasis in Estrogen Receptor Positive and Negative Breast Cancer

(2012) Ryung S. Kim et al.   PLoS One

Proliferation State and Polo-Like Kinase1 Dependence of Tumorigenic Colon Cancer Cells

(2012) Federica Francescangeli et al.   STEM CELLS

Distinct Types of Tumor-Initiating Cells Form Human Colon Cancer Tumors and Metastases

(2011) Sebastian M. Dieter et al.   Cell Stem Cell

Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group

(2011) J. G. Villablanca et al.   CLINICAL CANCER RESEARCH

Identification of Dihydroceramide Desaturase as a Directin VitroTarget for Fenretinide

(2011) Mehrdad Rahmaniyan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Enhanced anti-neuroblastoma activity of a fenretinide complexed form after intravenous administration

(2011) Roberta Carosio et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Docosohaexanoic acid-supplemented PACA44 cell lines and over-activation of Krebs cycle: An integrated proteomic, metabolomic and interactomic overview

(2011) Angelo D'Alessandro et al.   Journal of Proteomics

A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group

(2010) M. M. Moore et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Wnt activity defines colon cancer stem cells and is regulated by the microenvironment

(2010) Louis Vermeulen et al.   NATURE CELL BIOLOGY

Computational Identification of a p38SAPK-Regulated Transcription Factor Network Required for Tumor Cell Quiescence

(2009) A. P. Adam et al.   CANCER RESEARCH

Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer

(2009) Bryan J. Schneider et al.   INVESTIGATIONAL NEW DRUGS

Randomized Double-Blind 2 × 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in High-Risk Premenopausal Women

(2009) Andrea Decensi et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Fenretinide and Low-Dose Tamoxifen on Insulin Sensitivity in Premenopausal Women at High Risk for Breast Cancer

(2008) H. Johansson et al.   CANCER RESEARCH

Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity

(2008) L. Vermeulen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA